Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15592037 | 0.92 | RORC (1.00) | RORC | |
| SCHEMBL16968523 | 0.92 | RORC (1.00) | RORC | |
| SCHEMBL15567701 | 0.92 | RORC (1.00) | RORC | |
| SCHEMBL15567318 | 0.88 | RORC (1.00) | RORC | |
| SCHEMBL15592176 | 0.86 | RORC (1.00) | RORC | |
| SCHEMBL18896644 | 0.86 | RORC (1.00) | RORC | |
| SCHEMBL15592015 | 0.86 | RORC (1.00) | RORC | |
| SCHEMBL15568539 | 0.86 | RORC (1.00) | RORC | |
| SCHEMBL15592016 | 0.86 | RORC (1.00) | RORC | |
| SCHEMBL15569305 | 0.86 | RORC (1.00) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2920149-B1 | 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-03-20 | — | — | EP | claimed |
| US-9663522-B2 | 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-05-30 | — | — | US | claimed |
| EP-2920149-A2 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | claimed |
| US-20150218169-A1 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | claimed |
| WO-2014026330-A1 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | claimed |
| WO-2014028600-A2 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | claimed |
| EP-2920149-B1 | 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA-T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-03-20 | — | — | EP | disclosed |
| US-9663522-B2 | 3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2920149-A2 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20150218169-A1 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| WO-2014026330-A1 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028600-A2 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218169-A1 | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | RORC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.